| scholarly article | Q13442814 |
| P2093 | author name string | D Reinhardt | |
| S C Tyagi | |||
| H R Figulla | |||
| R Körfer | |||
| H H Sigusch | |||
| J Hensse | |||
| P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II | Q28369144 | ||
| Recent advances in matrix metalloproteinase inhibitors research. | Q33755841 | ||
| Matrix metalloproteinase inhibitors: applications in oncology. | Q33888231 | ||
| Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target | Q33895469 | ||
| Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). | Q36114898 | ||
| Matrix metalloproteinases and their inhibitors in connective tissue remodeling | Q37174661 | ||
| Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction | Q37527656 | ||
| Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. | Q38299970 | ||
| Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms | Q40669724 | ||
| Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease | Q40741643 | ||
| Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. | Q40871833 | ||
| Regulation of matrix metalloproteinases following cellular transformation | Q41209328 | ||
| Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation | Q41665154 | ||
| Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). | Q52534168 | ||
| Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. | Q53368936 | ||
| Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake Bothrops asper | Q59290755 | ||
| A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure | Q59599298 | ||
| Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure | Q62383757 | ||
| Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy | Q71616014 | ||
| Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases | Q72758247 | ||
| Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion | Q72789242 | ||
| Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus | Q72828910 | ||
| Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry | Q73091520 | ||
| Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat | Q73233103 | ||
| A tenascin knockout with a phenotype | Q73676246 | ||
| Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control | Q73682767 | ||
| Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat | Q73693685 | ||
| Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion | Q73824981 | ||
| Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation | Q74152272 | ||
| The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome | Q74601466 | ||
| Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms | Q77319343 | ||
| Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy | Q77540640 | ||
| Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function | Q78151176 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 525-530 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Heart | Q856338 |
| P1476 | title | Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. | |
| P478 | volume | 88 |
| Q41343627 | A New Hypothesis for Insulin Resistance in Hypertension Due to Receptor Cleavage |
| Q40000765 | A role of matrix metalloproteinase-8 in atherosclerosis |
| Q44959320 | AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction |
| Q95823842 | AT1receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: Detection using proteomics |
| Q42078470 | Apoptosis after reperfused myocardial infarction: Role of angiotensin II. |
| Q64239467 | Beyond Reperfusion: Acute Ventricular Unloading and Cardioprotection During Myocardial Infarction |
| Q42457121 | Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodelling in a rat model of acute myocardial infarction |
| Q35160121 | Bridge to recovery with the use of left ventricular assist device and clenbuterol |
| Q41230502 | Captopril and lisinopril only inhibit matrix metalloproteinase-2 (MMP-2) activity at millimolar concentrations |
| Q33249346 | Changes in connexin 43, metalloproteinase and tissue inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy in dogs |
| Q33239800 | Changes in metalloproteinase and tissue inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy by rapid atrial pacing in dogs |
| Q39255610 | Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. |
| Q43378616 | Dissecting the Role of the Extracellular Matrix in Heart Disease: Lessons from the Drosophila Genetic Model |
| Q64948935 | Effects of Curcumin Nanoparticles in Isoproterenol-Induced Myocardial Infarction. |
| Q45858813 | Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction |
| Q47098423 | Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. |
| Q81606863 | Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies |
| Q79424311 | Extracellular matrix turnover and disease severity in Anderson-Fabry disease |
| Q53646470 | Histological and biochemical outcomes of cardiac pathology in mdx mice with dietary quercetin enrichment. |
| Q51994063 | Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. |
| Q88726712 | Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload |
| Q44959333 | Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function |
| Q38584976 | Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice |
| Q26827231 | Management of fibrosis: the mesenchymal stromal cells breakthrough |
| Q99555872 | Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis |
| Q38224193 | Matrix metalloproteinases are involved in cardiovascular diseases |
| Q35636530 | Matrix metalloproteinases: pathways of induction by bioactive molecules |
| Q34460959 | Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis |
| Q35030016 | Metalloproteinase in myocardial adaptation and maladaptation |
| Q46990084 | Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. |
| Q35636517 | Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system |
| Q38121745 | Pacing-induced cardiomyopathy: pathophysiological insights through matrix metalloproteinases |
| Q34009450 | Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension |
| Q46916695 | Physiological regulation of MMPs and tPA/PAI in the arterial wall of rats by noradrenergic tone and angiotensin II. |
| Q33649673 | Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model |
| Q47960038 | Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study |
| Q37204147 | S-nitrosylation: specificity, occupancy, and interaction with other post-translational modifications |
| Q42154116 | Serum concentrations of metalloproteinase 2, metalloproteinase 9 and granzyme B in contact eczema patients |
| Q37774392 | Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. |
| Q40632807 | The effect of captopril on the expression of MMP-9 and the prognosis of neurological function in herpes simplex encephalitis mice |
| Q38091933 | The role of B-cells in heart failure |
| Q36915712 | Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. |
| Q53631060 | Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. |
| Q44633040 | Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure |
| Q50909884 | Type IV collagen degradation in the myocardial basement membrane after unloading of the failing heart by a left ventricular assist device. |
| Q36526885 | Zinc balance and medications commonly used in the management of heart failure |
Search more.